Suomi - suomi - Fimea (Suomen lääkevirasto)

accord healthcare b.v. - oxaliplatin - infuusiokonsentraatti, liuosta varten - 5 mg/ml - oksaliplatiini

Suomi - suomi - Fimea (Suomen lääkevirasto)

ratiopharm gmbh - paliperidone palmitate - injektioneste, depotsuspensio - 150 mg + 100 mg - paliperidoni

Suomi - suomi - Fimea (Suomen lääkevirasto)

ratiopharm gmbh - paliperidone palmitate - injektioneste, depotsuspensio - 150 mg - paliperidoni

Suomi - suomi - Fimea (Suomen lääkevirasto)

ratiopharm gmbh - paliperidone palmitate - injektioneste, depotsuspensio - 100 mg - paliperidoni

Suomi - suomi - Fimea (Suomen lääkevirasto)

ratiopharm gmbh - paliperidone palmitate - injektioneste, depotsuspensio - 75 mg - paliperidoni

Suomi - suomi - Fimea (Suomen lääkevirasto)

ratiopharm gmbh - paliperidone palmitate - injektioneste, depotsuspensio - 50 mg - paliperidoni

Suomi - suomi - Fimea (Suomen lääkevirasto)

ratiopharm gmbh - paliperidone palmitate - injektioneste, depotsuspensio - 25 mg - paliperidoni

Euroopan unioni - suomi - EMA (European Medicines Agency)

lipomed gmbh - deferiproni - iron overload; beta-thalassemia - kaikki muut terapeuttiset tuotteet - deferiproni lipomed-monoterapia on tarkoitettu hoitoon raudan ylikuormitus potilaille, joilla on talassemia major, kun nykyinen kelaatiohoidon hoito on vasta-aiheinen tai riittämätön. deferiproni lipomed yhdessä toisen kelatoi tehokkaasti on tarkoitettu potilaille, joilla on talassemia major, kun yksinään mitään rautaa kelatoi tehokkaasti on tehoton, tai kun ehkäisyyn tai hoitoon hengenvaarallisia seurauksia raudan ylikuormitus oikeuttaa nopea tai intensiivinen korjaus.

Euroopan unioni - suomi - EMA (European Medicines Agency)

lipomed gmbh - talidomidin - multiple myeloma - immunosuppressantit - thalidomide lipomed in combination with melphalan and prednisone is indicated as first line treatment of patients with untreated multiple myeloma, aged ≥ 65 years or ineligible for high dose chemotherapy. thalidomide lipomed is prescribed and dispensed in accordance with the thalidomide lipomed pregnancy prevention programme (see section 4.

Euroopan unioni - suomi - EMA (European Medicines Agency)

accord healthcare s.l.u. - doxorubicin hydrochloride, liposomal - ovarian neoplasms; sarcoma, kaposi; multiple myeloma - doxorubicin - zolsketil pegylated liposomal is a medicine used to treat the following types of cancer in adults:• breast cancer that has spread to other parts of the body in patients at risk of heart problems. zolsketil pegylated liposomal is used on its own for this disease;• advanced ovarian cancer in women whose previous treatment including a platinum-based cancer medicine has stopped working;• multiple myeloma (a cancer of the white blood cells in the bone marrow), in patients with progressive disease who have received at least one other treatment in the past and have already had, or are unsuitable for, a bone marrow transplantation. zolsketil pegylated liposomal is used in combination with bortezomib (another cancer medicine);• kaposi’s sarcoma in patients with aids who have a very damaged immune system. kaposi’s sarcoma is a cancer that causes abnormal tissue to grow under the skin, on moist body surfaces or on internal organs. zolsketil pegylated liposomal contains the active substance doxorubicin and is a ‘hybrid medicine’. this means that it is similar to a ‘reference medicine’ containing the same active substance called adriamycin. however, in zolsketil pegylated liposomal the active substance is enclosed in tiny fatty spheres called liposomes, whereas this is not the case for adriamycin.